Viking Therapeutics to Present at Upcoming Investor Conferences

Dienstag, 06.03.2018 13:00 von PR Newswire - Aufrufe: 24

PR Newswire

SAN DIEGO, March 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at three upcoming investor conferences.   

Details of these presentations are as follows:

  • 30th Annual ROTH Conference
    Time/Date: 3:00 p.m. PT on Tuesday, March 13, 2018
    Location: Ritz-Carlton Laguna Niguel, Dana Point, CA
    Room: Blue – Salon 2
  • H.C. Wainwright & Co.'s 2nd Annual NASH Investor Conference
    Time/Date: 10:40 p.m. ET on Monday, March 19, 2018
    Location: St. Regis Hotel, New York
  • Oppenheimer's 28th Annual Healthcare Conference
    Time/Date: 2:10 p.m. ET on Tuesday, March 20, 2018 (webcast available)
    Location: Westin New York Grand Central Hotel, New York
    Room: Track 61

To access the live webcast of Viking's Oppenheimer conference presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and non-alcoholic fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Follow Viking on Twitter @Viking_VKTX.


Cision View original content:

SOURCE Viking Therapeutics, Inc.

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


6,70 $
Viking Therapeutics Chart